Clinical Trial Update: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction [Phase 3]

View source ↗

Summary

Phase 3 trial assessing LIB003 for further LDL-C reduction in adults with heterozygous familial hypercholesterolemia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• LIB003

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED